Presidio Property Trust Inc Preferred Series D

NASDAQ SQFTP

Download Data

Presidio Property Trust Inc Preferred Series D Price to Sales Ratio (P/S) on June 03, 2024: 0.61

Presidio Property Trust Inc Preferred Series D Price to Sales Ratio (P/S) is 0.61 on June 03, 2024, a -51.44% change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.
  • Presidio Property Trust Inc Preferred Series D 52-week high Price to Sales Ratio (P/S) is 1.29 on June 12, 2023, which is 111.71% above the current Price to Sales Ratio (P/S).
  • Presidio Property Trust Inc Preferred Series D 52-week low Price to Sales Ratio (P/S) is 0.35 on October 27, 2023, which is -42.73% below the current Price to Sales Ratio (P/S).
  • Presidio Property Trust Inc Preferred Series D average Price to Sales Ratio (P/S) for the last 52 weeks is 0.74.
NASDAQ: SQFTP

Presidio Property Trust Inc Preferred Series D

CEO -
IPO Date June 11, 2021
Location United States
Headquarters 4995 Murphy Canyon Road, San Diego, CA, United States, 92123
Employees 15
Sector Real Estate
Industry Reit - diversified
Description

Presidio is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. Our office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California. While geographical clustering of real estate enables us to reduce our operating costs through economies of scale by servicing several properties with less staff, it makes us susceptible to changing market conditions in these discrete geographic areas, including those that have developed as a result of COVID-19. Presidio owns approximately 6.5% of the outstanding common stock of Conduit Pharmaceuticals Inc., a disease agnostic multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development.

Similar companies

ATLCP

Atlanticus Holdings Corp Preferred

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email